Infliximab biosimilar - Amgen

Drug Profile

Infliximab biosimilar - Amgen

Alternative Names: ABP-710

Latest Information Update: 22 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase I Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Preclinical Inflammation; Rheumatic disorders

Most Recent Events

  • 14 Jun 2017 Updated adverse events, pharmacokinetics and immunogenicity data from a phase I trial in Healthy subjects presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 11 Nov 2016 Adverse events, pharmacokinetics and immunogenicity data from a phase I trial in Healthy subjects presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 19 Oct 2016 Phase-III development planned for Rheumatoid arthritis and development is ongoing for Inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top